Carisbamate vs Lamotrigine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline
Carisbamate
Developed by SK Biopharmaceuticals Co., Ltd.
NCT00425282 · Phase 3 · completed
This randomized, double-blind, placebo-controlled Phase 3 study (study 1 of two identical trials) gave carisbamate 200 or 400 mg/day or placebo for 12 weeks to 565 adults with refractory partial-onset seizures. The registered primary endpoint was the change in partial-onset seizure frequency. The 400 mg/day dose met it (median reduction 27.27% vs 15.21% with placebo, P = 0.009, and the paper reports the responder rate was also significant at this dose), while 200 mg/day did not differ from placebo (P = 0.678). The primary endpoint was met at the higher dose and missed at the lower dose, so the result is mixed. Sources: EU Clinical Trials Register results (EudraCT 2006-003839-68) and Sperling et al., Epilepsia 2010.
Next expected readout: February 2027 · NCT05219617 (registry estimate)
Reported efficacy
The primary outcome is the change in seizure frequency of all simple partial motor, complex partial, or secondarily generalized seizures from the pretreatment baseline phase compared with the double-blind treatment phase.: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results). (mixed)
Result source: NCT00425282
Lamotrigine
Marketed by GlaxoSmithKline
NCT01431976 · Phase 3 · completed
This was a small, single-arm, open-label study of 20 participants, with no randomization, blinding, or comparator. The primary clinical endpoint found 7 of 20 participants (35%) seizure free by hyperventilation-EEG at the end of maintenance, but there was no formal between-group comparison.
Reported efficacy
Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 (missed)
Result source: NCT00088452
Results for Epilepsy
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Carisbamate | Lamotrigine |
|---|---|---|
| Seizure frequency, % change | —Not posted · NCT00433667 | 75.4% vs 32.1%+43.3 vs placeboNCT00104416 |
| 50% responder rate | —Not posted · NCT00433667 | —Not posted · NCT00007670 |
| Seizure freedom | —Not posted · NCT00433667 | —Not posted · NCT00007670 |
Seizure frequency, % change
- Carisbamate
- —Not posted · NCT00433667
- Lamotrigine
- 75.4% vs 32.1%+43.3 vs placeboNCT00104416
50% responder rate
- Carisbamate
- —Not posted · NCT00433667
- Lamotrigine
- —Not posted · NCT00007670
Seizure freedom
- Carisbamate
- —Not posted · NCT00433667
- Lamotrigine
- —Not posted · NCT00007670
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Carisbamate: 0 of 4 rows · Lamotrigine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lamotrigine |
|---|---|
| Dropout rate | 70%a NCT01431976 · Phase 3 · monotherapy show 16 more results0% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 — NCT02404168 · Phase 4 · registry result, not featured evidence — NCT01995825 · Phase 4 · registry result, not featured evidence 52.2% NCT01431963 · Phase 3 · registry result, not featured evidence — NCT00516139 · Phase 3 · registry result, not featured evidence 20% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 2%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 16.8%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 30.1%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 13.2% NCT00104416 · Phase 3 · registry result, not featured evidence 0% NCT00789113 · Phase 1/2 · registry result, not featured evidence — NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy |
| Discontinued due to AEs | 30%a NCT01431976 · Phase 3 · monotherapy show 16 more results— NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 — NCT02404168 · Phase 4 · registry result, not featured evidence — NCT01995825 · Phase 4 · registry result, not featured evidence 26.9% NCT01431963 · Phase 3 · registry result, not featured evidence — NCT00516139 · Phase 3 · registry result, not featured evidence 6.7% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 2%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 3.5%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 8.8%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 1.3% NCT00104416 · Phase 3 · registry result, not featured evidence — NCT00789113 · Phase 1/2 · registry result, not featured evidence — NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy |
| Serious AEs | 0%a NCT01431976 · Phase 3 · monotherapy show 16 more results1.3% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 0% NCT02404168 · Phase 4 · registry result, not featured evidence 0% NCT01995825 · Phase 4 · registry result, not featured evidence 12.3% NCT01431963 · Phase 3 · registry result, not featured evidence 18.2% NCT00516139 · Phase 3 · registry result, not featured evidence 3.3% NCT00292461 · Phase 3 · registry result, not featured evidence 3.9%Adolescents: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 9.8%Adults: LTG NCT00395694 · Phase 3 · registry result, not featured evidence 1.6%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —300 mg NCT00355082 · Phase 3 · registry result, not featured evidence 2.7%300 mg NCT00355082 · Phase 3 · registry result, not featured evidence —250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 4.5%250 mg NCT00355082 · Phase 3 · registry result, not featured evidence 1.4% NCT00104416 · Phase 3 · registry result, not featured evidence 0% NCT00789113 · Phase 1/2 · registry result, not featured evidence 0% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy |
| Most frequent reported AEs | show 13 more resultsfatigue 8.7% headache 8.1% hostility 6.7% NCT00088452 · Phase 3 · monotherapy · Absence Seizures, Epilepsy · phase 3 headache 11.4% dizziness 5.7% blurred vision 2.9% NCT01995825 · Phase 4 · registry result, not featured evidence nasopharyngitis 23.1% headache 21.5% rash 12.3% NCT01431963 · Phase 3 · registry result, not featured evidence dizziness 25.6% balance disorder 20.7% fall 18.2% NCT00516139 · Phase 3 · registry result, not featured evidence diplopia 10% dizziness 6.7% insomnia 6.7% NCT00292461 · Phase 3 · registry result, not featured evidence upper respiratory tract inflammation 29.4% nasopharyngitis 27.5% diarrhoea 21.6% NCT00395694 · Phase 3 · registry result, not featured evidence dizziness 19.6% nasopharyngitis 19.6% contusion 15.7% NCT00395694 · Phase 3 · registry result, not featured evidence 300 mg headache 17.9% dizziness 6% nausea 3.3% NCT00355082 · Phase 3 · registry result, not featured evidence 300 mg headache 25.9% dizziness 10.7% nasalpharyngitis 6.3% NCT00355082 · Phase 3 · registry result, not featured evidence 250 mg headache 27.9% rash 10.8% dizziness 9% NCT00355082 · Phase 3 · registry result, not featured evidence headache 13.9% (placebo 16.2%) vomiting 9.7% (placebo 4.1%) nausea 6.9% (placebo 5.4%) NCT00104416 · Phase 3 · registry result, not featured evidence somnolence 80% dizziness 66.7% headache 60% NCT03695094 · Phase 1 · registry result, not featured evidence · background therapy |
Notes
- aPopulation comparability has not been reviewed for 16 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lamotrigine
show 2 more results
show 2 more results
show 13 more results
show 1 more result
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carisbamate's landscape · Lamotrigine's landscape